{"acute kidney injury": 3.75, "adrenal insufficiency": 12.72, "adrenocorticotropic hormone deficiency": 22.97, "adverse event": 4.63, "amylase increased": 2.04, "anaemia": 2.04, "arthritis": 2.24, "atrioventricular block complete": 6.35, "autoimmune colitis": 40.38, "autoimmune haemolytic anaemia": 12.67, "autoimmune hepatitis": 15.44, "autoimmune hypothyroidism": 69.4, "autoimmune nephritis": 66.76, "autoimmune thyroiditis": 11.45, "blood pressure abnormal": 2.02, "blood thyroid stimulating hormone increased": 7.14, "cardiogenic shock": 2.08, "central nervous system lesion": 3.7, "cholangitis sclerosing": 18.07, "cholecystitis": 2.16, "cholestasis": 2.43, "colitis": 13.61, "conjunctivitis": 2.22, "cortisol decreased": 19.84, "dermatitis": 3.82, "dermatitis bullous": 4.16, "diabetes mellitus": 2.53, "diabetic ketoacidosis": 5.5, "drug effective for unapproved indication": 18.19, "drug eruption": 2.6, "drug-induced liver injury": 5.4, "encephalitis": 5.64, "encephalitis autoimmune": 21.58, "eosinophilic fasciitis": 68.28, "eyelid ptosis": 5.15, "febrile neutropenia": 2.33, "fulminant type 1 diabetes mellitus": 27.23, "gastritis": 2.88, "gastrointestinal toxicity": 6.22, "general physical health deterioration": 3.01, "guillain-barre syndrome": 2.3, "haematotoxicity": 2.78, "haemophagocytic lymphohistiocytosis": 5.3, "hepatic cytolysis": 3.0, "hepatitis": 11.42, "hepatitis cholestatic": 5.11, "hepatotoxicity": 9.0, "hydronephrosis": 4.24, "hyperthyroidism": 11.15, "hypertransaminasaemia": 9.12, "hypocalcaemia": 2.44, "hypophysitis": 30.26, "hypopituitarism": 10.8, "hypothyroidism": 20.08, "ill-defined disorder": 2.28, "immune thrombocytopenia": 3.29, "immune-mediated adrenal insufficiency": 9.64, "immune-mediated adverse reaction": 165.91, "immune-mediated arthritis": 143.49, "immune-mediated dermatitis": 78.41, "immune-mediated encephalitis": 66.78, "immune-mediated enterocolitis": 63.16, "immune-mediated gastritis": 109.38, "immune-mediated hepatic disorder": 13.87, "immune-mediated hepatitis": 114.05, "immune-mediated hyperthyroidism": 59.8, "immune-mediated hypophysitis": 51.71, "immune-mediated hypothyroidism": 76.58, "immune-mediated lung disease": 159.14, "immune-mediated myasthenia gravis": 106.66, "immune-mediated myocarditis": 147.52, "immune-mediated myositis": 154.2, "immune-mediated nephritis": 76.48, "immune-mediated neuropathy": 48.1, "immune-mediated pancreatitis": 75.36, "immune-mediated thyroiditis": 202.74, "immune-mediated uveitis": 65.21, "inappropriate schedule of product administration": 4.17, "interstitial lung disease": 3.31, "lichen planus": 6.82, "lichenoid keratosis": 18.65, "lymphocytic hypophysitis": 36.53, "malignant neoplasm progression": 16.9, "mucosal inflammation": 3.92, "multi-organ disorder": 31.67, "myasthenia gravis": 22.01, "myasthenia gravis crisis": 22.62, "myasthenic syndrome": 34.65, "myocarditis": 3.87, "myopathy": 5.09, "myositis": 15.94, "nephritis": 28.8, "nephropathy toxic": 5.08, "neutropenia": 2.33, "ocular myasthenia": 38.8, "off label use": 2.5, "ophthalmoplegia": 10.77, "organising pneumonia": 15.29, "palmar-plantar erythrodysaesthesia syndrome": 2.74, "pancytopenia": 2.67, "pemphigoid": 19.37, "performance status decreased": 2.07, "pneumonitis": 25.98, "pneumothorax": 2.15, "polyarthritis": 15.35, "polymyalgia rheumatica": 10.32, "posterior reversible encephalopathy syndrome": 3.26, "prescribed underdose": 4.03, "primary hypothyroidism": 99.67, "product use in unapproved indication": 9.21, "product use issue": 7.41, "proteinuria": 4.59, "psoriasis": 2.31, "pulmonary fibrosis": 3.55, "pulmonary mass": 2.17, "pulmonary toxicity": 9.19, "radiotherapy": 23.67, "rash maculo-papular": 3.32, "renal cyst": 3.45, "renal tubular necrosis": 7.51, "respiratory failure": 2.56, "sarcoidosis": 9.23, "secondary adrenocortical insufficiency": 18.94, "sjogren's syndrome": 10.12, "skin toxicity": 21.0, "stevens-johnson syndrome": 6.35, "stomatitis": 2.27, "therapy non-responder": 9.26, "therapy partial responder": 85.88, "thyroiditis": 17.8, "toxic epidermal necrolysis": 13.84, "toxic skin eruption": 3.01, "toxicity to various agents": 3.68, "troponin increased": 2.23, "tubulointerstitial nephritis": 21.42, "tumour hyperprogression": 229.66, "tumour pseudoprogression": 142.33, "type 1 diabetes mellitus": 29.42, "uveitis": 3.27, "vasculitis": 3.06, "vitiligo": 38.58}